Connect with us

Technology

Lunit and Volpara Unveiled Unified Ecosystem at RSNA 2024 to Transform Global Cancer Care

Published

on

Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care

SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ — At this year’s RSNA 2024 Annual Meeting, Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, and Volpara Health, a Lunit company and a global leader in mammography AI  for the early detection of cancer, announced their unified vision, focusing on a comprehensive Ecosystem for early cancer detection, cancer risk prediction, and autonomous AI for enhanced clinical workflows.

 

A Growing Ecosystem for Cancer Detection and Care

At the core of Lunit and Volpara’s unified strategy is a comprehensive Ecosystem designed to support clinicians and improve patient outcomes across the entire cancer journey. The Ecosystem delivers actionable insights that enhance care quality and efficiency by integrating AI-driven technologies for lesion detection, workflow optimization, and patient engagement, with decision-making insight through risk prediction and mammography quality control. Powered by world-class AI, including physics-based algorithms and access to over 130 million images for research and development, the Ecosystem drives accurate, efficient, and scalable solutions for cancer detection.

Focusing on customer obsession, the Ecosystem also provides dedicated support, professional services, and fosters an exclusive online community to ensure clinical success and operational excellence. Additionally, future multipliers like autonomous AI, intelligent report generation, and image-based risk evaluation are set to redefine the standards of cancer care globally.

Lunit INSIGHT Risk and Volpara Risk Pathways: Transforming Risk Assessment

As part of their collaboration, Lunit and Volpara presented a powerful combination of Lunit INSIGHT Risk and Volpara Risk Pathways, offering a comprehensive approach to breast cancer risk management.

Lunit INSIGHT Risk uses AI-driven imaging data to predict breast cancer risk within 1-5 years, providing actionable insights based on mammography images.Volpara Risk Pathways incorporates clinical and lifestyle data to deliver broader, personalized risk assessments.

Together, these solutions enable clinicians to create tailored care plans, enhance early detection strategies, and ensure equitable care for diverse patient populations.

Expanding AI Innovation: Autonomous Chest X-Ray Report Generation

At RSNA 2024, Lunit also introduced its Autonomous AI Chest X-ray Report Generation prototype, showcasing its potential to revolutionize diagnostic workflows. Using advanced foundation models, the system automates chest X-ray interpretations and generates structured reports. By analyzing and categorizing findings based on severity, measurement, and location, the tool ensures precision and standardization in reporting.

This innovation significantly reduces radiologist workloads, especially in high-volume clinical environments, while improving diagnostic efficiency. By automating time-consuming processes, it enables radiologists to focus on complex and critical cases, ensuring timely and accurate patient care.

As an additional feature, the tool includes voice recognition capabilities, allowing radiologists to make edits and finalize reports seamlessly, further enhancing workflow flexibility and usability.

Driving Global Market Expansion

The collaboration between Lunit and Volpara underscores their shared commitment to conquering cancer together and leading the global fight against cancer. Together, they aim to expand their presence in key markets by leveraging the Ecosystem, advanced AI solutions like Lunit INSIGHT Risk, and innovative tools such as autonomous report generation.

“This year’s RSNA marks an important milestone in our collaboration with Volpara,” said Brandon Suh, CEO of Lunit. “By integrating our complementary technologies, we are transforming the way clinicians detect cancer, predict risk, and manage workflows. This Ecosystem is more than a set of tools. It’s a global solution designed to empower healthcare providers, reduce disparities, and ultimately save more lives; the next frontier in cancer care.”

“Our partnership with Lunit has allowed us to combine decades of expertise in AI and personalized care to create a truly unified Ecosystem,” said Teri Thomas, CEO of Volpara Health and CBO of Lunit Cancer Screening Group. “Together, as part of the same family, we’re addressing some of the most pressing challenges in cancer care—from empowering clinicians with actionable insights to improving outcomes for patients around the world. We’re proud to showcase the tangible impact of this integration, which is already shaping the future of global cancer detection and care.”

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. We harness AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,500 hospitals and medical institutions across 55+ countries.

Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.

 

About Volpara Health

Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara’s software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit www.volparahealth.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunit-and-volpara-unveiled-unified-ecosystem-at-rsna-2024-to-transform-global-cancer-care-302323898.html

SOURCE Lunit

Continue Reading

Technology

Epson to Showcase Collaborative 6-Axis Robot and Integrated Automation Solutions at The ASSEMBLY Show 2026

Published

on

By

AX6 Cobot and Live Demonstrations Highlight Epson’s Expanding Automation Portfolio

LOS ALAMITOS, Calif., Oct. 21, 2026 /PRNewswire/ — Epson Robots, the #1 SCARA robot manufacturer in the world, will showcase its expanding automation portfolio, including its first collaborative robot, the AX6, at The ASSEMBLY Show 2026, taking place in Rosemont, Illinois from Oct. 27-29, 2026, in booth #331.

Epson to Showcase AX6 Cobot and Integrated Automation Solutions with Live Demos at The ASSEMBLY Show 2026

“Every automation application has different safety requirements, and there is no one-size-fits-all approach,” said Scott Marsic, group product manager, Epson Robots. “With the AX6 and SafeSenseTM technology, Epson is giving manufacturers more options to select the right solution for their requirements. At The ASSEMBLY Show, we look forward to demonstrating how these offerings complement our broader robotics portfolio and help manufacturers address a wide range of automation needs.”

With Epson’s latest automation technologies, attendees can experience live demonstrations showcasing integrated robotics, vision, and feeding solutions. The live applications will highlight practical, cost-effective solutions for real-world production environments. An educational speaking session will also focus on selecting the right automation approach for each application. Epson highlights at The ASSEMBLY Show 2026 will include:

Speaking Engagement”Automation Isn’t the Answer. Choosing the Right Automation Is.” – Marsic will outline a practical framework for choosing the right automation strategy, from evaluating opportunities and avoiding application creep to balancing critical design considerations such as safety, robot geometry, workcell design and flexibility. The session will focus on solving the right business problem to create automation systems that are easier to implement, scale and maintain while delivering stronger productivity, reliability and long-term ROI. The session will take place Wednesday, October 28 from 2 – 2:30 p.m. at the Learning Theater.AX6 Collaborative 6-Axis Robot – See Epson’s first collaborative robot in action, featuring a lightweight, compact footprint and intuitive no-code software designed to simplify programming and deployment. Power- and force-limiting capabilities and flexible end-of-arm options support collaborative applications where space, ease of use and fast redeployment are priorities.SafeSense Interactive Demo – Experience a hands-on demonstration of Epson’s SafeSense technology, which uses sensors to detect when a person enters the robot’s workspace, supporting safe human-robot interaction while maintaining high-performance automation.IntelliFlexTM Feeding System – See live demonstrations featuring Epson’s latest SCARA and 6-Axis robots integrated with IntelliFlex Feeding Systems for automated part handling and assembly applications.Epson RC+® Development Software – Explore Epson’s PC-based environment with intuitive GUI Builder for custom interfaces along with integrated vision and IntelliFlex capabilities. Developed and supported by Epson, the software is designed to simplify automation development and deployment.

The ASSEMBLY Show 2026 will take place on Oct. 27 from 4 p.m. to 7 p.m. CDT, Oct. 28 from 10 a.m. to 5 p.m. CDT and Oct. 29 from 9 a.m. to 2 p.m. CDT at the Donald E. Stephens Convention Center in Rosemont, Illinois. To learn more about Epson robot solutions at the show, stop by booth #331 or visit www.epsonrobots.com to contact a robot expert.

About Epson Robots

Epson Robots is a global leader in PC-controlled precision factory automation, with well over 250,000 units sold worldwide1 and a product line of hundreds of models of easy-to-use SCARA and 6-Axis robots based on a common PC-based platform. Building on four decades of experience, Epson Robots delivers robots for precision assembly and material handling applications in the aerospace, appliance, automotive, biotechnology, consumer product, electronics, food processing, medical device, pharmaceutical, plastics, semiconductor, and telecommunication industries. For more information, visit www.epsonrobots.com.

About Epson

Epson is a technology innovation and engineering company whose philosophy of efficient, compact and precise innovation enriches lives and helps create a better world. The company uses technology and engineering ability to implement real-world solutions in precision innovation, industrial and robotics, office and home printing, and visual and lifestyle.

Led by the Japan-based Seiko Epson Corporation, the worldwide Epson Group generates annual sales of more than JPY 1.4 trillion. corporate.epson/en/

Epson America, Inc., based in Los Alamitos, Calif., is Epson’s regional headquarters for the U.S., Canada and Latin America. To learn more about Epson, please visit: epson.com. You may also connect with Epson America on Facebook (facebook.com/Epson), X (x.com/EpsonAmerica), YouTube (youtube.com/epsonamerica) and Instagram (instagram.com/EpsonAmerica).

1 Epson internal sales data through April 2026.

EPSON and Epson RC+ are registered trademarks of Seiko Epson Corporation. SafeSense and IntelliFlex are trademarks of Epson America, Inc. All other product and brand names are trademarks and/or registered trademarks of their respective companies. Epson disclaims any and all rights in these marks. Copyright 2026 Epson America, Inc.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/epson-to-showcase-collaborative-6-axis-robot-and-integrated-automation-solutions-at-the-assembly-show-2026-302915812.html

SOURCE Epson America, Inc.

Continue Reading

Technology

Limber Health Launches Recovery Forecast, the First-Ever Predicted Outcomes Solution for Rehab Therapy

Published

on

By

Built on the largest risk-adjusted patient outcomes database in rehab therapy, Limber’s Recovery Forecast replaces traditional single point-in-time forecasts or MCID comparisons with a 90-day outlook

PITTSBURGH, Oct. 21, 2026 /PRNewswire/ — Limber Health, a Net Health company, today announced Recovery Forecast, the first-ever predicted outcomes trajectory solution for rehab therapy. Built into the Limber outcomes platform, Recovery Forecast maps each patient’s expected path throughout care by comparing them with millions of completed assessments and applying robust risk adjustment. Available to clients this fall, this new clinical capability covers the primary MSK regions of injury.

“Current solutions show a point-in-time measurement, but rarely provide context or insight into the score,” said Nirav Modi, president of Limber Health. “Recovery Forecast shows clinicians how a patient is progressing through their plan of care, so they can assess, adjust, and guide them toward the best possible improvement.”

Because Limber Outcomes follows patients from evaluation through the full episode of care, the expected path stays visible between visits. At intake, the feature predicts each patient’s path; then at each reassessment, clinicians compare the actual score with the prediction for real-time context. This gives clinicians an opportunity to adjust the course of care.

“Being able to predict a patient’s outcome trajectory is a game changer,” said Brian Kelly, Vice President of Innovation & Clinical Excellence at Ivy Health. “It transforms outcomes data into real-time clinical intelligence that enhances patient engagement, empowers proactive clinical decision-making, and ensures every patient is positioned for an optimal recovery.”

A newly developed progression indicator, the Predicted Moderate Clinical Improvement (P-MCI), marks where a patient is expected to reach clinically meaningful improvement. P-MCI is already part of commercial payer quality programs. It underpins five functional improvement measures in the CMS proposed rule for the 2027 Physician Fee Schedule, with Limber Health and Patient360 as measure stewards. For more information about Limber Recovery Forecast, click here. 

About Limber Health

Limber Health, a Net Health company, extends in-person musculoskeletal (MSK) care into the home with Remote Therapeutic Monitoring (RTM), Home Exercise Programs (HEP), and Limber Outcomes, which helps practices measure patient progress and predict recovery using the largest risk-adjusted patient outcomes database in rehab therapy. Limber’s solutions are developed by physical therapists and physicians. Learn more at www.limberhealth.com.

About Net Health

For over 30 years, Net Health has gathered specialty knowledge shaped by human expertise and informed by patient outcomes. Today, this depth of knowledge is the foundation for an AI-native specialty platform that delivers intelligence to clinicians across the care continuum, enabling them to be present with patients during the moments that matter. Net Health is a trusted source of specialty solutions for more than 34,000 healthcare organizations, and is a portfolio company of The Carlyle Group, Level Equity, and Silversmith Capital Partners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/limber-health-launches-recovery-forecast-the-first-ever-predicted-outcomes-solution-for-rehab-therapy-302915819.html

SOURCE Net Health Systems, Inc.

Continue Reading

Technology

Asuri.ai Launches Multi-Agent AI Platform for Persistent Business Workflows

Published

on

By

The agentic platform helps nontechnical teams save time, eliminate redundant work and deploy specialized AI agents across more than 1,000 existing applications

IRVINE, Calif., Oct. 21, 2026 /PRNewswire/ — Asuri today announced the launch of its multi-agent enterprise AI platform, designed to help businesses move beyond copilots and deploy persistent AI workflows across complete business processes.

As AI models become more capable, the challenge for businesses is shifting from generating answers to safely giving AI the context, system access and autonomy required to perform real work.

Asuri brings those pieces into one platform.

Nontechnical teams can define a business process, connect the applications involved, assign specialized agents to different responsibilities, and control what each agent can access, recommend or execute. By coordinating work that would otherwise require employees to repeatedly move between systems, gather information and perform routine follow-ups, Asuri helps organizations save time and remove redundant manual work.

“The model itself is becoming less of the bottleneck,” said Artem Bespaloff, CEO and co-founder of Asuri. “The harder problem is coordinating agents across real business systems while giving each one the right context, permissions and level of autonomy.”

Unlike traditional AI assistants that primarily respond to prompts, Asuri is designed around persistent multi-agent workflows.

Asuri combines multi-agent orchestration, workflow logic, persistent context and agent-level permission controls in a single environment, with more than 1,000 integrations connecting agents to the software businesses already use.

This allows companies to automate processes across existing systems instead of replacing their technology stack, reducing repetitive administrative work and freeing employees to focus on higher-value decisions and relationships.

As part of its launch, Asuri is introducing prebuilt customer intelligence workflows that consolidate information from multiple business systems, analyze client activity against company-defined rules, and automatically alert employees to significant developments. By eliminating the need to manually track client activity across different platforms, these workflows reduce the workload on sales and research teams, helping them stay informed, identify opportunities, and focus on higher-value activities.

The same architecture can support workflows across sales, operations, finance, customer success, research and internal compliance.

Businesses can learn more and request access at Asuri.ai.

About Asuri

Asuri is a multi-agent enterprise AI platform, built by Sprouter Technologies, for persistent, governed business workflows. With more than 1,000 integrations, Asuri helps organizations connect specialized AI agents across their existing applications, reduce repetitive work, save employee time and automate processes while maintaining individual permissions, autonomy boundaries and human oversight.

For more information you can contact team@asuri.ai

View original content to download multimedia:https://www.prnewswire.com/news-releases/asuriai-launches-multi-agent-ai-platform-for-persistent-business-workflows-302915829.html

SOURCE Sprouter Technologies

Continue Reading

Trending